Monopar Therapeutics Inc. (MNPR) News
Follow Monopar Therapeutics Inc. (MNPR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Monopar appoints Jeffrey D. Kent EVP, Head of Medical Affairs
Monopar appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs, and announces two ALXN1840 presentations at AASLD — The Liver Meeting® 2026.
EQUITY | Aug 19, 2026, 12:00 PM UTC
L
Clsa, Cantor, RBC, Wolfe, JPM cut ratings on several stocks
Multiple brokers issue rating changes: AMC to Hold at CLSA, BETR to Neutral at Cantor, LENZ to Neutral at BofA, MNPR to Neutral at Cantor, OI to Sector Perform at RBC, SYK to Peer Perform at Wolfe, and TROX to Underweigh
EQUITY | Aug 13, 2026, 10:50 AM UTC
L
MNPR Reports Q2 2026 Financial Results
Monopar Therapeutics reports second quarter 2026 financial results and provides business updates
EARNINGS | Aug 12, 2026, 01:30 PM UTC
L
Monopar Says FDA Grants Rare Pediatric Disease Designation To ALXN1840, Late-Stage Candidate For Treatment Of Wilson Disease
Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ: MNPR ), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the U.S. Foo
REGULATION | Jun 30, 2026, 12:03 PM UTC
M
HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $105 Price Target
HC Wainwright maintains Buy rating on Monopar Therapeutics.
EQUITY | Jun 29, 2026, 10:26 AM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Tuesday's intraday session, with Aditxt and Atlantic International leading the gainers and Trinity Biotech and Tenon Medical leading the losers
EQUITY | Jun 23, 2026, 05:09 PM UTC